Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
Cardio Diagnostics is Pumping February 6, 2023
Faraday Future Running on $135 M Financing Commitments Expected to Provide Sufficient Funding to Reach March 2023 Production Milestone February 6, 2023
GD Culture Group Higher on Increased Volume February 6, 2023
HeartSciences near Ascendiant‘s $3.30 Target Price February 3, 2023
Genetic Technologies pulls back after Announcing $5M Registered Direct Offering February 3, 2023
Next
Prev

Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer

  • May 9, 2022 at 5:24 AM

VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer

Read the entire article here.

RelatedNews

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.